Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development ... takes the form of stem cell-derived ...

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Planforge today announced Planforge 25, the latest release of its industry-leading project work management software. The new ...

This was attributed to ongoing development efforts and expenses related to new product launches. Vertex's non-GAAP EPS decrease to $3.98, from $4.20 in the previous year, underscores these cost ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $459 from $450 and keeps an Equal ...

Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.

As expected, the bulk of Vertex's revenue came from its flagship cystic fibrosis (CF) treatment, Trikafta/Kaftrio. However, the "other product revenue" category could start to become more of a factor.

Vertex Pharmaceuticals Inc (VRTX) reports robust financial performance with significant revenue growth and strategic product launches, despite facing international IP challenges. Biotech company ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

There are fundamental reasons to see the World Bank's report Localizing Development, by Ghazala Mansuri and Vijayendra Rao, as one of the most important books on development in recent years. " The ...